Parkinson’s Disease: Start-Ups Seek Breakthroughs And Money
This article was originally published in Start Up
Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.
You may also be interested in...
TwoXAR Inc. wants to help the biopharma industry make good use of big data. The start-up hopes to change the way drug discovery works, with software that can analyze broad arrays of data – chemical compound libraries, gene expression data, protein interaction networks, protein binding databases, patient records and just about anything else related to drug development – and propose a "short list" of drug candidates with a high probability of making it to the clinic.
Prexton Therapeutics aims to advance the standard of care for Parkinson’s disease by developing a therapeutic that strategically targets metabotropic glutamate receptor 4. It plans to use its lead compound as an add-on therapy to facilitate lower therapeutic doses of L-dopa in order to decrease adverse effects, while maintaining the expected therapeutic level of the treatment.
Parkure Ltd., based in a small lab in Edinburgh, Scotland, will use its fruit fly assay to find new Parkinson’s disease treatments from old drugs, with an aim to slow or even reverse the course of this devastating CNS disorder.